Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:alternativeName |
gptkb:deucravacitinib
|
| gptkbp:approvalYear |
2022
|
| gptkbp:approvedBy |
gptkb:European_Union
gptkb:United_States |
| gptkbp:ATCCode |
L04AA56
|
| gptkbp:CASNumber |
1609392-27-9
|
| gptkbp:chemicalFormula |
C22H19F2N5O2
|
| gptkbp:clinicalTrialPhase |
Phase 3
|
| gptkbp:developedBy |
gptkb:Bristol_Myers_Squibb
|
| https://www.w3.org/2000/01/rdf-schema#label |
BMS-986165
|
| gptkbp:indication |
psoriasis
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
TYK2 inhibitor
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea headache upper respiratory tract infection |
| gptkbp:target |
gptkb:TYK2
|
| gptkbp:bfsParent |
gptkb:TYK2
|
| gptkbp:bfsLayer |
8
|